Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Fabrizio Bert, Giacomo Scaioli, Lorenzo Vola, Davide Accortanzo, Giuseppina Lo Moro and Roberta Siliquini
Additional contact information
Fabrizio Bert: Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy
Giacomo Scaioli: Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy
Lorenzo Vola: Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy
Davide Accortanzo: Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy
Giuseppina Lo Moro: Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy
Roberta Siliquini: Department of Public Health Sciences and Pediatrics, University of Turin, 10126 Turin, Italy

IJERPH, 2022, vol. 19, issue 12, 1-16

Abstract: The need for an anti-COVID-19 booster dose posed an organizational challenge for health policy makers worldwide. Therefore, this study aimed to explore the health policies regarding the booster dose through an overview of recommendations issued in high-income countries. Between 10 November and 16 December 2021, the authors searched for state-level official documents about the offer of the booster dose, considering the 43 countries belonging to the European Union (EU) or the Organisation for Economic Co-operation and Development (OECD). Mainly due to the lack of English translation, 15 countries were excluded. A total of 135 documents were selected. Almost all the countries started administering the booster dose between September and November 2021. The most used products were mRNA vaccines, followed by Vaxzevria-AstraZeneca and Jcovden-Janssen/Johnson & Johnson. All countries established criteria to define categories of individuals to be vaccinated as a priority. A six/five-months interval was the main choice for general population vaccinated with mRNA vaccines, while shorter intervals were chosen for vulnerable individuals or other vaccines. Despite diversities related to the differences in health systems, economical resources, and population numbers, and the need to adapt all these factors to a massive vaccination campaign, a progressive convergence towards the same vaccination policies was highlighted.

Keywords: health care policy; booster dose; COVID-19; vaccine (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/12/7233/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/12/7233/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:12:p:7233-:d:837702

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().